Developing the next generation of oral ketamine and pharmaceutical marijuana analogs to treat neurologic neuropsychiatric disorders

Improved Therapies with Potential Results

With small changes, MIRA’s technology focuses on big effects that have the potential to redefine therapeutic outcomes, opening up new markets for indications and patients.

Learn About MIRA-55
Learn About Ketamir

Latest News

Detailed Stock Information
Mon Oct 28, 2024 07:30 am

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.

Detailed Stock Information
View Investor Relations

Symbol
NASDAQ: MIRA
Price
$
Volume
Change
{'1d_range' | i8ln tLang}
{scope.data.dayLow | asQHLast tLang}
{scope.data.dayHigh | asQHLast tLang}
{'52weekrange' | i8ln tLang}
{scope.data.week52Low | asQHLast tLang}
{scope.data.week52High | asQHLast tLang}

Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Terms of Use.